Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-6dd92eeff0b9acf2637c14b216fa6b97"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-6dd92eeff0b9acf2637c14b216fa6b97"/>
<resource>
<Composition>
<id value="composition-en-6dd92eeff0b9acf2637c14b216fa6b97"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-6dd92eeff0b9acf2637c14b216fa6b97"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-6dd92eeff0b9acf2637c14b216fa6b97</b></p><a name="composition-en-6dd92eeff0b9acf2637c14b216fa6b97"> </a><a name="hccomposition-en-6dd92eeff0b9acf2637c14b216fa6b97"> </a><a name="composition-en-6dd92eeff0b9acf2637c14b216fa6b97-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1657/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - kinpeygo</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1657/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp6dd92eeff0b9acf2637c14b216fa6b97"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - kinpeygo"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Kinpeygo is and what it is used for</li><li>What you need to know before you take Kinpeygo</li><li>How to take Kinpeygo</li><li>Possible side effects</li><li>How to store Kinpeygo</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What kinpeygo is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What kinpeygo is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Kinpeygo contains the active substance budesonide, a corticosteroid medicine which mainly acts locally in the intestine to reduce the inflammation associated with primary immunoglobulin A (IgA) nephropathy.</p><p>Kinpeygo is used to treat primary IgA nephropathy in adults 18 years of age or older.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take kinpeygo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take kinpeygo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Kinpeygo:</p><ul><li>If you are allergic to budesonide or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have loss of function of your liver that your doctor has told you is severe .</li></ul><p>Warnings and precautions<br/>Talk to your doctor or pharmacist before taking Kinpeygo:</p><ul><li>If you are going to have surgery.</li><li>If you have liver problems.</li><li>If you are taking or have recently taken corticosteroids.</li><li>If you have recently had an infection.</li><li>If you have active or quiescent tuberculosis infection, untreated fungal, bacterial, systemic viral or parasitic infections, or ocular herpes simplex.</li><li>If you have high blood pressure.</li><li>If you have diabetes or someone in your family has had diabetes.</li><li>If you have brittle bones (osteoporosis).</li><li>If you have stomach ulcers.</li><li>If you have glaucoma (increased pressure in the eye) or cataracts or someone in your family has had glaucoma (increased pressure in the eye).</li></ul><p>If any of the above apply to you, you may be at increased risk of side effects. Your doctor will decide on the appropriate measures and if it is still all right for you to take this medicine.</p><p>Look out for side effects If you get blurred vision or other sight problems, contact your doctor. See section 4 for more information.</p><p>Chickenpox or measles Illnesses like chickenpox and measles can be more serious if you are taking this medicine. If you have not yet had these illnesses, keep away from people with chicken pox or measles while taking this medicine. Tell your doctor if you think that you have been infected with chicken pox or measles while taking this medicine.</p><p>Adrenal function tests Kinpeygo could affect the results of adrenal function tests (ACTH stimulation test) ordered by your doctor. Tell your doctors that you are taking Kinpeygo before you have any tests.</p><p>Children and adolescents Kinpeygo should not be used in children and adolescents below 18 years of age. The use of this medicine in children younger than 18 years of age has not been studied.</p><p>Other medicines and Kinpeygo Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, and herbal medicines.</p><p>This is because Kinpeygo capsules can affect the way some medicines work and some medicines can have an effect on Kinpeygo capsules.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><ul><li>Ketoconazole or itraconazole - to treat infections caused by a fungus.</li><li>Medicines for HIV called protease inhibitors - such as ritonavir, indinavir and saquinavir.</li><li>Erythromycin - an antibiotic used to treat infections.</li><li>Cyclosporin - used to suppress your immune system.</li><li>Carbamazepine - for epilepsy and nerve pain problems.</li><li>Cardiac glycosides - such as digoxin- medicines used to treat heart conditions.</li><li>Diuretics - to remove excess fluid from the body.</li></ul><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Kinpeygo.</p><p>Kinpeygo with food and drink Do not eat grapefruit or drink grapefruit juice while you are taking Kinpeygo. It can affect the way the medicine works.</p><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Do not take this medicine during pregnancy without checking with your doctor first.</p><p>Do not take this medicine if you are breast-feeding unless you have checked with your doctor. Budesonide passes in small amounts into the breast milk. Your doctor will help you decide whether you should continue treatment and not breast-feed or if you should stop treatment over the period your baby is being breast-fed.</p><p>Driving and using machines Kinpeygo is not expected to affect your ability to drive or use any machines.</p><p>Kinpeygo contains sucrose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p></div>
</text>
</section>
<section>
<title value="3. How to take kinpeygo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take kinpeygo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>How to take The recommended dose of Kinpeygo is 16 mg (4 capsules of Kinpeygo 4 mg) once daily. Take in the morning, at least 1 hour before a meal.</p><ul><li>Swallow whole with a glass of water.</li><li>Do not open, crush or chew as this could affect the release of the medicine. The capsules have a special coating, to ensure that the medicine is released in the correct part of your gut.</li></ul><p>When treatment is to be discontinued, your doctor will reduce the dose to 8 mg (2 capsules of Kinpeygo 4 mg) once daily for the last 2 weeks of therapy. If considered necessary by your doctor, the dose may then be reduced to 4 mg once daily (1 capsule of Kinpeygo 4 mg) for another 2 weeks.</p><p>If you take more Kinpeygo than you should If you take more Kinpeygo than you should, talk to a doctor or pharmacist straight away. Take the carton with you.</p><p>If you have taken more than you should for a long time, the possible side effects listed in section 4 may appear.</p><p>If you forget to take Kinpeygo If you miss a dose of Kinpeygo, wait and take the medicine the next day as usual.<br/>Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Kinpeygo Do not stop taking Kinpeygo without discussing it with your doctor first. If you suddenly stop taking the medicine, you may become ill.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor if you notice any of the following side effects with this medicine:</p><p>Common (may affect up to 1 in 10 people)</p><ul><li>Increased blood pressure</li><li><pre><code>Swelling of arms or legs such as ankle swelling </code></pre></li><li><pre><code>Cushingoid features such as a rounded face, increased body hair, weight gain and acne </code></pre></li><li>Indigestion</li><li>Muscle cramps</li><li>Rash or itchy skin</li><li>Weight gain</li><li>Diabetes mellitus</li></ul><p>Rare (may affect up to 1 in 1 000 people)</p><ul><li>Blurred vision</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.* By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store kinpeygo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store kinpeygo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the bottle label. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Kinpeygo contains</p><ul><li><p>The active substance is budesonide. Each modified-release hard capsule contains 4 mg of budesonide.</p></li><li><p>The other ingredients are: Capsule content: Sugar spheres (sucrose and corn starch), hypromellose, macrogol, citric acid monohydrate, ethylcellulose, medium chain triglycerides, oleic acid (see also section 2 Kinpeygo contains sucrose ). Capsule shell: Hypromellose, macrogol, titanium dioxide (E171), methacrylic acid-methyl methacrylate co-polymers, talc, dibutyl sebacate,<br/>Printing ink: Shellac, black iron oxide (E172).</p></li></ul><p>What Kinpeygo looks like and contents of the pack Kinpeygo 4 mg modified-release hard capsules are 19 mm white coated opaque capsules printed with CAL10 4MG in black ink.</p><p>The capsules are supplied in a white high-density polyethylene (HDPE) bottle with a white polypropylene (PP) child-resistant closure with an induction seal. This medicine is available in bottles containing 120 modified-release hard capsules and in multipacks of 360 modified-release hard capsules comprising 3 bottles, each containing 120 modified-release hard capsules.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder<br/>STADA Arzneimittel AG Stadastrasse 2-61118 Bad Vilbel Germany</p><p>Manufacturer</p><p>Tjoapack Netherlands B.V. Nieuwe Donk 9 4879 AC Etten-Leur Noord-Brabant Netherlands</p><p>STADA Arzneimittel AG<br/>Stadastrasse 2 61118 Bad Vilbel<br/>Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder :</p><p>Belgi /Belgique/Belgien<br/>EG (Eurogenerics) NV<br/>T l/Tel: +32 24797Lietuva<br/>UAB STADA Baltics<br/>Tel: +370 52603<br/>STADA Bulgaria EOOD<br/>Te .: +359 29624Luxembourg/Luxemburg<br/>EG (Eurogenerics) NV<br/>T l/Tel: +32 24797 esk republika<br/>STADA PHARMA CZ s.r.o. Tel: +420 257888Magyarorsz g<br/>STADA Hungary Kft<br/>Tel.: +36 18009Danmark STADA Nordic ApS Tlf: +45 44859Malta Pharma.MT Ltd. Tel: + 356 21337Deutschland<br/>STADAPHARM GmbH<br/>Tel: +49 61016Nederland<br/>Centrafarm B.V.<br/>Tel.: +31 765081Eesti UAB STADA Baltics<br/>Tel: +370 52603Norge<br/>STADA Nordic ApS Tlf: +45 44859<br/>F RAN S.A. : +30 2106254 sterreich STADA Arzneimittel GmbH<br/>Tel: +43 136785Espa a Laboratorio STADA, S.L.<br/>Tel: +34 934738Polska STADA Poland Sp. z o.o. Tel: +48 227377France EG Labo - Laboratoires EuroGenerics<br/>T l: +33 146948Portugal Stada, Lda. Tel: +351 211209Hrvatska STADA d.o.o. Tel: +385 13764Rom nia STADA M&D SRL<br/>Tel: +40 213160Ireland Clonmel Healthcare Ltd.<br/>Tel: +353 526177Slovenija Stada d.o.o. Tel: +386 15896 sland STADA Nordic ApS Tlf: +45 44859Slovensk republika STADA PHARMA Slovakia, s.r.o.<br/>Tel: +421 252621Italia EG SpA Tel: +39 028310Suomi/Finland STADA Nordic ApS, Suomen sivuliike<br/>Puh/Tel: +358 207416<br/>STADA Arzneimittel AG<br/>: +30 2106664Sverige STADA Nordic ApS<br/>Tel: +45 44859Latvija UAB STADA Baltics<br/>Tel: +370 52603United Kingdom (Northern Ireland) STADA Arzneimittel AG<br/>Tel: +49 61016This leaflet was last revised in 07/2023 .</p><p>This medicine has been given conditional approval . This means that there is more evidence to come about this medicine.</p><p>The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp6dd92eeff0b9acf2637c14b216fa6b97"/>
<resource>
<MedicinalProductDefinition>
<id value="mp6dd92eeff0b9acf2637c14b216fa6b97"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp6dd92eeff0b9acf2637c14b216fa6b97"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp6dd92eeff0b9acf2637c14b216fa6b97</b></p><a name="mp6dd92eeff0b9acf2637c14b216fa6b97"> </a><a name="hcmp6dd92eeff0b9acf2637c14b216fa6b97"> </a><a name="mp6dd92eeff0b9acf2637c14b216fa6b97-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1657/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Kinpeygo 4 mg modified-release hard capsules</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1657/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Kinpeygo 4 mg modified-release hard capsules"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
